omniture
logo
Search
信达生物制药（苏州）有限公司 Innovent BiologicsInc
Media Room

Latest News

rss

Innovent Announces First Patient Outside China Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody

SAN FRANCISCO and SUZHOU, China, March 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-03-01 08:23 7343

The BCMA CAR-T Co-developed by Innovent and IASO Was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Multiple Myeloma

SAN FRANCISCO and SUZHOU, China, Feb. 23, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-02-23 09:22 6402

Innovent Announces First Patient Dosed in Phase III Pivotal Trial of IBI310 (CTLA-4) Combined with TYVYT® (sintilimab injection) for the Treatment of First-line Advanced Hepatocellular Carcinoma

SAN FRANCISCO and SUZHOU, China, Feb. 9, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2021-02-09 08:00 8975

Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, Feb. 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (...

2021-02-03 12:30 10132

Innovent Announces an Out-license Agreement with PT Etana Biotechnologies Indonesia to Launch BYVASDA® (Bevacizumab Biosimilar) in Indonesia

SAN FRANCISCO and SUZHOU, China, Jan. 19, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-01-19 08:00 8385

Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for TYVYT® (sintilimab injection) in Combination with BYVASDA® (bevacizumab injection) as First-Line Therapy in Hepatocellular Carcinoma (HCC)

SAN FRANCISCO and SUZHOU, China, Jan. 13, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-01-13 08:00 6671

Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab as Second-Line Therapy for Squamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, Jan. 12, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-01-12 13:02 6869

Innovent Announces the NMPA Granted New Indication Approval for BYVASDA® (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma

SAN FRANCISCO and SUZHOU, China, Dec. 28, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2020-12-28 08:00 8947

Innovent Announces NMPA Granted New Indication Approvals for SULINNO® (Adalimumab Injection) for the Treatment of Pediatric Plaque Psoriasis and Non-infectious Uveitis

SAN FRANCISCO and SUZHOU, China, Dec. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2020-12-23 12:30 9576

Innovent Announces First Patient Dosed in Phase 2 Pivotal Trial of IBI310 (CTLA-4) combined with TYVYT® (sintilimab injection) for the treatment of second-line or above Advanced Cervical Cancer

SAN FRANCISCO and SUZHOU, China, Dec. 11, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2020-12-11 09:02 7913

Innovent Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

SAN FRANCISCO and SUZHOU, China, Dec. 8, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2020-12-08 08:00 5533
1 ... 1112131415